Drug
Bimekizumab clinical trials
Also written UCB4940 and Bimzelx.
Keep track of what changes. Save the bimekizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2019 (7)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 9
UCB Biopharma SRL (32) · UCB Biopharma S.P.R.L. (5) · UCB Celltech (3) · Icahn School of Medicine at Mount Sinai (1) · Radboud University Medical Center (1) · University Hospital, Rouen (1) · Mayo Clinic (1) · Oregon Health and Science University (1)
Often tested with
Tested in the same studies.
Secukinumab (3) · Ixekizumab (3) · Guselkumab (3) · Risankizumab (3) · Certolizumab Pegol (3) · Tildrakizumab (2) · Tacrolimus (2) · Adalimumab (2)
Studies
Open first, then newest update. How each study uses bimekizumab is read from its arms, and is right about nine times in ten.
Testing it · 49
- An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisRecruitingPhase 3UCB Biopharma SRLNCT06668181Written as Bimekizumab
- Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?RecruitingPhase 2Centre Hospitalier Universitaire de NiceNCT06742333Written as Bimekizumab
- Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of BimekizumabNot yet recruitingPhase 3University Hospital, RouenNCT07836283Written as bimekizumab
- A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)RecruitingPhase 1UCB Biopharma SRLNCT06888193Written as Bimekizumab
- Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)Not yet recruitingPhase 4Mayo ClinicNCT07497620Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisRecruitingPhase 3UCB Biopharma SRLNCT07219420Written as Bimekizumab
- Efficacy of Bimekizumab in Adults With Pyoderma GangrenosumNot yet recruitingPhase 2Oregon Health and Science UniversityNCT07767864Written as Bimekizumab
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Bimekizumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3UCB Biopharma SRLNCT04242446Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3UCB Biopharma SRLNCT04242498Written as Bimekizumab
- A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3UCB Biopharma SRLNCT04901195Written as Bimekizumab
- A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedPhase 3UCB Biopharma SRLNCT03895203Written as Bimekizumab
- A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingPhase 3UCB Biopharma SRLNCT06921850Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial SpondyloarthritisCompletedPhase 3UCB Biopharma SRLNCT03928704Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedPhase 3UCB Biopharma SRLNCT03896581Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing SpondylitisCompletedPhase 3UCB Biopharma SRLNCT03928743Written as Bimekizumab
- A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisCompletedPhase 3UCB Biopharma SRLNCT04436640Written as Bimekizumab
- A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedPhase 3UCB Biopharma SRLNCT04009499Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompletedPhase 3UCB Biopharma SRLNCT06624228Written as Bimekizumab
See all 49 studies that test bimekizumab →
Given in every arm · 5 — bimekizumab is usual care beside what is tested
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)RecruitingPhase 2Spyre Therapeutics, Inc.NCT07766005Written as bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3UCB Biopharma SRLNCT06425549Written as bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3UCB Biopharma SRLNCT03412747Written as Bimekizumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3UCB Biopharma SRLNCT03536884Written as Bimekizumab
- Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid ArthritisCompletedPhase 2UCB CelltechNCT02430909Written as Bimekizumab
Codes
What other systems call bimekizumab · ClinicalTrials.gg INT000884
- MeSH (NLM) C000625981bimekizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 09495UIM6VBIMEKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q60785566bimekizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171829BimekizumabOne source FDA
- DrugBank DB12917One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625981 | bimekizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 09495UIM6V | BIMEKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q60785566 | bimekizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171829 | Bimekizumab | One source FDA |
| DrugBank | DB12917 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.